Anthony Murray,Carsten Ryttersgaard,Daniel Rodriguez Greve,Erik Rytter Ottosen,Gunnar Grue-Sorensen,Simon Feldbaek Nielsen,Soren Christian Schou,Tina Dahlerup Poulsen
申请号：
BR112012000422
公开号：
BR112012000422A2
申请日:
2010.07.08
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
The invention relates to compounds of general formula (I) wherein A, R1, R2, R3, R4, R5, R9, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use&mdash；alone or in combination with one or more other pharmaceutically active compounds&mdash；in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.
